Atypical Ulcerated Lesions in a Patient With Cogan Syndrome (original) (raw)
2017, Actas Dermo-Sifiliográficas (English Edition)
AI-generated Abstract
Cogan syndrome (CS) is a rare autoimmune vasculitis primarily known for causing recurrent interstitial keratitis and audiovestibular symptoms. This report highlights a unique case of a 39-year-old woman with CS who developed multiple ulcerated lesions across her body, which initially resembled ecthyma. Despite antibiotic treatment, the lesions worsened until steroid therapy was employed, leading to resolution. This case underscores the potential for atypical skin manifestations in CS and suggests a need for further investigation into the disease's cutaneous aspects.
Related papers
BMJ Case Reports, 2018
pyoderma gangrenosum (pG) coexisting with Cogan's syndrome (Cs) is uncommon, although cutaneous manifestations are known to develop in Cs. a middleaged white female patient had chronic relapsing pG requiring ciclosporin and prednisolone. Despite receiving optimal doses of ciclosporin and prednisolone, she developed acute vestibulo-auditory symptoms as a result of Cs. Ciclosporin was switched to methotrexate and prednisolone was increased. However, she continued to develop acute scleritis, requiring methylprednisolone pulses, and still had further flares of pG. Her methotrexate was held off when she developed severe pneumonia and she then received a trial of intravenous immunoglobulins (IVIG) for her recurrent leg ulcers. Unfortunately, she failed to respond to IVIG. Her ulcers eventually responded to six doses of monthly intravenous cyclophosphamide induction. although Cs is not an antineutrophil cytoplasmic antibodies (aNCa)-associated vasculitis, we used pulse cyclophosphamide, based on the experience of cyclophosphamide efficacy in severe aNCa-associated vasculitis (aaV). Following induction, both diseases currently remain under control with azathioprine as maintenance treatment.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.